FDA approves first therapy for Alexander disease - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

  • By

  • Kathryn Wighton

  • September 4, 2026

  • 2 min

Share

Clinical Report: FDA approves first therapy for Alexander disease

Overview

The FDA has approved zilganersen (Zanvastro) injection for patients with Alexander disease, a rare neurological condition.

Background

Alexander disease is a rare, progressive neurologic disorder caused by mutations affecting glial fibrillary acidic protein (GFAP) production. The disease leads to severe neurological symptoms and affects fewer than 1 in 1 million people.

Data Highlights

Age GroupOutcomeResults
5 years and olderWalking speedSignificantly better with zilganersen at 61 weeks
2 to 4 yearsMotor assessmentImproved in zilganersen group, control group declined

Key Findings

  • Zilganersen is an antisense oligonucleotide targeting GFAP.
  • FDA approval was based on a multicenter, randomized, controlled study of 49 patients.
  • Patients aged 5 years and older showed significant improvement in walking speed at 61 weeks.
  • Patients aged 2 to 4 years improved on a broader motor assessment.
  • Common adverse reactions include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.
  • Aseptic meningitis has been reported in patients treated with zilganersen.

Clinical Implications

Clinicians should be aware of the common adverse reactions associated with this therapy.

Conclusion

The approval of zilganersen marks a milestone in the management of Alexander disease.

Related Resources & Content

  1. US Food and Drug Administration, FDA, 2026 -- FDA Approves First Drug to Treat Alexander Disease
  2. the asco post — FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
  3. retinal physician — FDA Clears Gene Therapy Trial for GA
  4. MDSpire News — FDA Approves First Drug for Thymidine Kinase 2 Deficiency
  5. the asco post — Newly Diagnosed AL Amyloidosis: FDA Grants Traditional Approval to Regimen
  6. FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
  7. FDA Clears Gene Therapy Trial for GA
  8. FDA Approves First Drug for Thymidine Kinase 2 Deficiency
  9. FDA Approves First Drug to Treat Alexander Disease | FDA
  10. Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting | Ionis Pharmaceuticals, Inc.
  11. Alexander Disease - GeneReviews® - NCBI Bookshelf

Original Source(s)

FDA approves first therapy for Alexander disease

  • by Kathryn Wighton

  • September 4, 2026

Related Content

Baptist Health Brain & Spine Care to Host 14th Annual Miami Neuroscience Symposium Nov. 4-6, Bringing Leading Experts Together to Explore Advances in Brain and Spine Care

Baptist Health will bring together leading physicians, researchers and healthcare professionals from South Florida and across the country for the 14th Annual Baptist Health Miami Neuroscience Symposium, taking place Nov. 4-6, 2026, at Hilton Miami Dadeland and virtually via Zoom.

  • by

  • August 21, 2026

  • 5 min
Volatility priors may reveal delusion severity in schizophrenia

Expectations of environmental instability declined alongside delusional symptoms during 6 months following an acute psychotic episode.

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.